FDA, Biosimilar and Insulin
FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved in 2021 by the FDA. Approval of biosimilar products can increase patient access to safe and effective treatment options.
fast-acting insulin analogs, insulin pens using disposable needles and insulin pumps installed with a catheter in the abdomen. Melbourne, Australia-based Phosphagenics has an insulin patch in ...
In an awake individual, mild-to-moderate nocturnal hypoglycemia is easily corrected by ingesting a snack containing approximately 5 g of fast-acting carbohydrate ... the basal insulin, a bedtime ...
Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin that is Lilly’s top selling drug, bringing in almost $700 ...
In 1999, we introduced rapid-acting and, in 2004, long-acting insulin analogues produced by genetic engineering, allowing users to mimic physiological insulin secretion to avoid ...
Because the hospital has one preferred formulary manufacturer for insulin analogues ... to the insulin pen group and prescribed any rapid-acting insulin (insulin lispro or insulin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback